Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

ADC Therapeutics (ADCT) EBIAT (2019 - 2026)

ADC Therapeutics has reported EBIAT over the past 8 years, most recently at -$33.0 million for Q1 2026.

  • Quarterly results put EBIAT at -$33.0 million for Q1 2026, up 14.6% from a year ago — trailing twelve months through Mar 2026 was -$137.0 million (up 8.99% YoY), and the annual figure for FY2025 was -$142.6 million, up 9.64%.
  • EBIAT reached -$33.0 million in Q1 2026 per ADCT's latest filing, down from -$6.4 million in the prior quarter.
  • Across five years, EBIAT topped out at $4.3 billion in Q3 2022 and bottomed at -$85.0 million in Q4 2023.
  • Median EBIAT over the past 5 years was -$38.6 million (2025), compared with a mean of $451.2 million.
  • The largest annual shift saw EBIAT soared 96342174.44% in 2022 before it tumbled 351893.21% in 2023.
  • Over 5 years, EBIAT stood at -$24157.0 in 2022, then crashed by 351893.21% to -$85.0 million in 2023, then skyrocketed by 62.05% to -$32.3 million in 2024, then surged by 80.14% to -$6.4 million in 2025, then plummeted by 414.4% to -$33.0 million in 2026.
  • Business Quant data shows EBIAT for ADCT at -$33.0 million in Q1 2026, -$6.4 million in Q4 2025, and -$41.0 million in Q3 2025.